Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of [14C]-LY3537982 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3537982
Drug: [¹⁴C]-LY3537982

First Posted Date: 2023-06-13

Last Posted Date: 2024-11-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT05901311

Locations: 🇺🇸
Labcorp Clinical Research Unit Inc., Madison, Wisconsin, United States

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LOXO-783
Drug: Cholestyramine

First Posted Date: 2023-06-08

Last Posted Date: 2023-09-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 21

Registration Number: NCT05894928

Locations: 🇺🇸
Labcorp Clinical Research Unit, Dallas, Texas, United States

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

Not Applicable

Completed

Conditions: Type 1 Diabetes
Type 2 Diabetes
Type 2 Diabetes Treated With Insulin

Interventions: Drug: Insulin Lispro
Device: Tempo Smart Button
Device: Dexcom G6 CGM
Device: Glooko Research Medical App (RMA)

First Posted Date: 2023-06-08

Last Posted Date: 2024-11-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT05893797

Locations: 🇫🇷
Centre Hospitalier Sud Francilien-Pharmacie, Corbeil-Essonnes, France
🇫🇷
CHU de Caen Hôpital Cote de Nacre, Caen, Cedex 9, France
🇫🇷
Chu de Grenoble, Grenoble Cédex 9, France

and more 6 locations

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY3532226
Drug: Placebo

First Posted Date: 2023-06-05

Last Posted Date: 2024-03-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT05887999

Locations: 🇺🇸
ProSciento, Inc, Chula Vista, California, United States

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Phase 1

Completed

Conditions: Healthy
Hepatic Insufficiency

Interventions: Drug: LY3502970

First Posted Date: 2023-05-31

Last Posted Date: 2024-12-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT05882032

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Phase 3

Active, not recruiting

Conditions: Obesity
Cardiovascular Diseases

Interventions: Drug: Retatrutide
Drug: Placebo

First Posted Date: 2023-05-31

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1800

Registration Number: NCT05882045

Locations: 🇦🇺
Camden Hospital, Camden, New South Wales, Australia
🇨🇦
Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada
🇸🇰
Human Care s.r.o., Kosice, Košický Kraj, Slovakia

and more 162 locations

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Phase 3

Active, not recruiting

Conditions: Overweight
Obesity
Type 2 Diabetes

Interventions: Drug: Orforglipron
Drug: Placebo

First Posted Date: 2023-05-24

Last Posted Date: 2024-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1500

Registration Number: NCT05872620

Locations: 🇦🇺
Advara HeartCare Joondalup, Joondalup, Western Australia, Australia
🇺🇸
Cahaba Research - Pelham, Pelham, Alabama, United States
🇺🇸
Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States

and more 132 locations

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Phase 3

Active, not recruiting

Conditions: Obesity
Overweight
Overweight or Obesity

Interventions: Drug: Placebo
Drug: Orforglipron

First Posted Date: 2023-05-22

Last Posted Date: 2024-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 3000

Registration Number: NCT05869903

Locations: 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸
Velocity Clinical Research, Huntington Park, Huntington Park, California, United States
🇺🇸
Velocity Clinical Research, Westlake, Los Angeles, California, United States

and more 135 locations

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3537982
Drug: Itraconazole
Drug: Carbamazepine

First Posted Date: 2023-05-16

Last Posted Date: 2024-11-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT05860933

Locations: 🇺🇸
ICON Early Development Services, Salt Lake City, Utah, United States

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Phase 4

Completed

Conditions: Psoriatic Arthritis
Plaque Psoriasis

Interventions: Drug: Ixekizumab

First Posted Date: 2023-05-12

Last Posted Date: 2024-10-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 250

Registration Number: NCT05855967

Locations: 🇮🇳
Oyster & Pearl Hospitals (Phadnis Clinic Pvt. Ltd.), Pune, Maharashtra, India
🇮🇳
Postgraduate Institute of Medical Education & Research, Chandigarh, Punjab, India
🇮🇳
Wizderm Specialty Skin And Hair Clinic, Kolkata, West Bengal, India

and more 11 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy